1
|
Halvorsen SC, Benita Y, Hopton M, Hoppe B, Gunnlaugsson HO, Korgaonkar P, Vanderburg CR, Nielsen GP, Trepanowski N, Cheah JH, Frosch MP, Schwab JH, Rosenberg AE, Hornicek FJ, Sassi S. Transcriptional Profiling Supports the Notochordal Origin of Chordoma and Its Dependence on a TGFΒ1-TBXT Network. Am J Pathol 2023; 193:532-547. [PMID: 36804377 DOI: 10.1016/j.ajpath.2023.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Revised: 12/23/2022] [Accepted: 01/26/2023] [Indexed: 02/19/2023]
Abstract
Chordoma is a rare malignant tumor demonstrating notochordal differentiation. It is dependent on brachyury (TBXT), a hallmark notochordal gene and transcription factor, and shares histologic features and the same anatomic location as the notochord. In this study, we perform a molecular comparison of chordoma and notochord to identify dysregulated cellular pathways. The lack of a molecular reference from appropriate control tissue limits our understanding of chordoma and its relationship to notochord. Accordingly, we conducted an unbiased comparison of chordoma, human notochord, and an atlas of normal and cancerous tissue using gene expression profiling to clarify the chordoma/notochord relationship and potentially identify novel drug targets. We found striking consistency in gene expression profiles between chordoma and notochord, supporting the hypothesis that chordoma develops from notochordal remnants. We identified a 12-gene diagnostic chordoma signature and found that the TBXT/transforming growth factor (TGF)-β/SOX6/SOX9 pathway is hyperactivated in the tumor, suggesting that pathways associated with chondrogenesis are a central driver of chordoma development. Experimental validation in chordoma cells confirms these findings and emphasizes the dependence of chordoma proliferation and survival on TGF-β. Our computational and experimental evidence provides the first molecular connection between notochord and chordoma and identifies core members of a chordoma regulatory pathway involving TBXT. This pathway provides new therapeutic targets for this unique malignant neoplasm and highlights TGF-β as a prime druggable candidate.
Collapse
Affiliation(s)
- Stefan C Halvorsen
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Yair Benita
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Megan Hopton
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Brooke Hoppe
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Hilmar Orn Gunnlaugsson
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Parimal Korgaonkar
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Charles R Vanderburg
- Harvard NeuroDiscovery Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts
| | - G Petur Nielsen
- Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts
| | - Nicole Trepanowski
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Jaime H Cheah
- High Throughput Sciences Facility, Koch Institute of MIT, Cambridge, Massachusetts
| | - Matthew P Frosch
- C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Charlestown, Massachusetts
| | - Joseph H Schwab
- Department of Orthopedic Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts
| | - Andrew E Rosenberg
- Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts
| | - Francis J Hornicek
- Department of Orthopedic Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
| | - Slim Sassi
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts; Department of Orthopedic Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
| |
Collapse
|
2
|
Bates J, Shrestha S, Liu Q, Smith S, Mulrooney D, Leisenring W, Gibson T, Robison L, Chow E, Oeffinger K, Armstrong G, Constine L, Hoppe B, Lee C, Yasui Y, Howell R. OC-0208 Cardiac substructure dosimetry and late cardiac arrhythmia in the Childhood Cancer Survivor Study. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06823-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Shrestha S, Gupta A, Bates J, Lee C, Owens C, Hoppe B, Constine L, Smith S, Qiao Y, Weathers R, Howell R. PH-0286: Development of CT-based cardiac model with substructure for dosimetry in late effects studies. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00310-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
von Allmen N, Gorzelniak K, Liesenfeld O, Njoya M, Duncan J, Marlowe EM, Hartel T, Knaust A, Hoppe B, Walter M. Liquid and Dry Swabs for Culture- and PCR-Based Detection of Colonization with Methicillin-Resistant Staphylococcus aureus during Admission Screening. Eur J Microbiol Immunol (Bp) 2019; 9:131-137. [PMID: 31934365 PMCID: PMC6945996 DOI: 10.1556/1886.2019.00022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 11/13/2019] [Indexed: 12/18/2022] Open
Abstract
Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) colonization status facilitates isolation and decolonization and reduces MRSA infections. Liquid but not dry swabs allow fully automated detection methods. However, the accuracy of culture and polymerase chain reaction (PCR) using liquid and dry swabs has not been analyzed. We compared different swab collection systems for routine nasal–throat MRSA screening in patients admitted to a tertiary care trauma center in Germany. Over 3 consecutive months, dry swabs (month 1), ESwabs (month 2), or MSwabs (month 3) were processed using Cepheid GeneXpert, Roche cobas and BD-MAX™ MRSA tests compared to chromogenic culture. Among 1680 subjects, the MRSA detection rate using PCR methods did not differ significantly between dry swabs, ESwab, and MSwab (6.0%, 6.2%, and 5.3%, respectively). Detection rates using chromogenic culture were 2.9%, 3.9%, and 1.9%, using dry, ESwab, and MSwab, respectively. Using chromogenic culture as the “gold standard”, negative predictive values for the PCR tests ranged from 99.2–100%, and positive predictive values from 33.3–54.8%. Thus, efficient and accurate MRSA screening can be achieved using dry, as well as liquid E- or MSwab, collection systems. Specimen collection using ESwab or MSwab facilitates efficient processing for chromogenic culture in full laboratory automation while also allowing molecular testing in automated PCR systems.
Collapse
Affiliation(s)
- N von Allmen
- Bereich Studien, Kooperationen & Innovationsmanagement, Labor Berlin - Charité Vivantes Services GmbH, Berlin, Germany
| | - K Gorzelniak
- Institut für Laboratoriumsmedizin, Unfallkrankenhaus Berlin, Germany
| | - O Liesenfeld
- Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, California
| | - M Njoya
- Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, California
| | - J Duncan
- Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, California
| | - E M Marlowe
- Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton, California
| | - T Hartel
- Klinik für Unfallchirurgie und Orthopäde, Unfallkrankenhaus Berlin, Germany
| | - A Knaust
- Fachbereich für Mikrobiologie, Labor Berlin - Charite Vivantes GmbH, Berlin, Germany
| | - B Hoppe
- Institut für Laboratoriumsmedizin, Unfallkrankenhaus Berlin, Germany
| | - M Walter
- Institute of Clinical Chemistry and Laboratory Medicine; Rostock University Medical Center, Rostock, Germany
| |
Collapse
|
5
|
van't Hoff W, Cochat P, Groothoff J, Harambat J, Frishberg Y, Hulton S, Magen D, Hoppe B, Lieske J, Milliner D, Deschenes G. SUN-325 SAFETY AND EFFICACY OF LUMASIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAi) THERAPEUTIC, IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.734] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
6
|
Häupl T, Skapenko A, Hoppe B, Skriner K, Burkhardt H, Poddubnyy D, Ohrndorf S, Sewerin P, Mansmann U, Stuhlmüller B, Schulze-Koops H, Burmester GR. [Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark]. Z Rheumatol 2019; 77:16-23. [PMID: 29691690 DOI: 10.1007/s00393-018-0458-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Rheumatic diseases are among the most common chronic inflammatory disorders. Besides severe pain and progressive destruction of the joints, rheumatoid arthritis (RA), spondyloarthritides (SpA) and psoriatic arthritis (PsA) impair working ability, reduce quality of life and if treated insufficiently may enhance mortality. With the introduction of biologics to treat these diseases, the demand for biomarkers of early diagnosis and therapeutic stratification has been growing continuously. The main goal of the consortium ArthroMark is to identify new biomarkers and to apply modern imaging technologies for diagnosis, follow-up assessment and stratification of patients with RA, SpA and PsA. With the development of new biomarkers for these diseases, the ArthroMark project contributes to research in chronic diseases of the musculoskeletal system. The cooperation between different national centers will utilize site-specific resources, such as biobanks and clinical studies for sharing and gainful networking of individual core areas in biomarker analysis. Joint data management and harmonization of data assessment as well as best practice characterization of patients with new imaging technologies will optimize quality of marker validation.
Collapse
Affiliation(s)
- T Häupl
- Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland.
| | - A Skapenko
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, München, Deutschland
| | - B Hoppe
- Zentralinstitut für Laboratoriumsmedizin und Pathobiochemie, Charité, Berlin, Deutschland
| | - K Skriner
- Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland
| | - H Burkhardt
- Abteilung für Rheumatologie, Johann-Wolfgang-Goethe-Universität, Frankfurt, Deutschland
| | - D Poddubnyy
- Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Berlin, Deutschland
| | - S Ohrndorf
- Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland
| | - P Sewerin
- Medizinische Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität, Düsseldorf, Deutschland
| | - U Mansmann
- Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität, München, Deutschland
| | - B Stuhlmüller
- Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland
| | - H Schulze-Koops
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, München, Deutschland
| | - G-R Burmester
- Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland
| |
Collapse
|
7
|
Weigert A, Hoppe B. Nephrolithiasis und Nephrokalzinose im Kindesalter. Monatsschr Kinderheilkd 2019. [DOI: 10.1007/s00112-019-0668-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Frishberg Y, Deschenes G, Cochat P, Magen D, Groothoff J, Hulton S, Harambat J, Van’t Hoff W, Hoppe B, Lieske J, McGregor T, Tamimi N, Haslett P, Talamudupula S, Erbe D, Milliner D. A safety and efficacy study of lumasiran, an investigational RNA interference (RNAi) therapeutic, in adult and pediatric patients with primary hyperoxaluria type 1. ACTA ACUST UNITED AC 2019. [DOI: 10.1016/s1569-9056(19)30291-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Woodward G, Pryke R, Hoppe B, Rumsby G. Rapid liquid chromatography tandem mass-spectrometry screening method for urinary metabolites of primary hyperoxaluria. Ann Clin Biochem 2018; 56:232-239. [DOI: 10.1177/0004563218811365] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background The primary hyperoxalurias are inherited disorders of glyoxylate metabolism that lead to overproduction of oxalate, urolithiasis and renal failure. Delays in diagnosis can be costly in terms of preserving renal function. Here we present a rapid liquid chromatography tandem mass-spectrometry screening method for the analysis of metabolites (primary hyperoxaluria metabolites) produced in excess by primary hyperoxaluria patients that include glycolate, glycerate and 2,4-dihydroxyglutarate. Methods Assay performance was compared to our existing gas chromatography–mass spectrometry method and clinical utility established by analysis of urine samples from patients with confirmed primary hyperoxalurias (11 PH1, 12 PH2 and 8 PH3) and controls ( n = 12). An additional 67 urine samples from patients with PH3 were used postvalidation to confirm the derived 2,4-dihydroxyglutarate cut-off. Results Glycolate, glycerate and 2,4-dihydroxyglutarate showed a mean bias of 3.3, −22.8 and 5.7%, respectively, compared to our previously published gas chromatography–mass spectrometry method. The mean total imprecision for glycolate, glycerate and 2,4-dihydroxyglutarate was shown to be 6.4, 10 and 11%, respectively. Clinical assessment confirmed that mean urinary glycolate, glycerate and 2,4-dihydroxyglutarate excretion were significantly elevated in patients with PH1, PH2 and PH3, respectively. The greatest sensitivity and specificity for PH1, PH2 and PH3 was achieved at cut-offs of 193, 100 and 4.9 μmol/mmol for glycolate, glycerate and 2,4-dihydroxyglutarate, respectively. Conclusions A rapid screening method for the identification and differentiation of patients with suspected PH1, PH2 and PH3 is presented that allows focussing of genetic testing, saving time, money and, with earlier treatment, potential preservation of renal function for these patients.
Collapse
Affiliation(s)
- G Woodward
- Department of Manual Biochemistry, Health Services Laboratories, London, UK
| | - R Pryke
- Department of Manual Biochemistry, Health Services Laboratories, London, UK
| | - B Hoppe
- Division of Paediatric Nephrology, University Children’s Hospital, Bonn, Germany
| | - G Rumsby
- Department of Manual Biochemistry, Health Services Laboratories, London, UK
| |
Collapse
|
10
|
Herm J, Hoppe B, Kasabov R, Malzahn U, Endres M, Koscielny J, Jungehulsing GJ, Haeusler KG. Thrombophilia screening in young patients with cryptogenic stroke. Hamostaseologie 2017; 32:147-52. [DOI: 10.5482/ha-1175] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Accepted: 12/02/2011] [Indexed: 11/05/2022] Open
Abstract
SummaryThe clinical relevance of thrombophilia screening in stroke patients is still a matter of debate, and descriptions of larger patterns of genetic variability are rare. We assessed the frequency of hereditary hypercoagulability in young patients with cryptogenic stroke (n = 44) and in healthy blood donors (n = 282) without prior cardiovascular event. Furthermore, we focused on the impact of thrombophilia screening on secondary stroke prevention. Results: Compared to the control group (19–67 years; median 38.5 years; 64% women), there was a lower prevalence of the FVII-R353Q mutation (p = 0.033) in stroke patients (17–52 years; median 36 years; 59.1% women). Of note, the FVII-R353Q mutation lowers FVII plasma levels, probably reducing the risk of cardiovascular events. The prevalence of the remaining 13 gene polymorphisms did not differ significantly. However, the prevalence of FV Leiden mutation tended to be higher among stroke patients. Conclusion: Overall, extended screening for inherited thrombophilia had an impact on medical stroke prevention in every sixth patient with cryptogenic stroke.
Collapse
|
11
|
Petzold T, Thienel M, Konrad I, Schubert I, Regenauer R, Hoppe B, Lorenz M, Eckart A, Chandraratne S, Lennerz C, Kolb C, Braun D, Jamasbi J, Brandl R, Braun S, Siess W, Schulz C, Massberg S. Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. Sci Transl Med 2016; 8:367ra168. [DOI: 10.1126/scitranslmed.aad6712] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 08/31/2016] [Indexed: 12/13/2022]
|
12
|
Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2016; 187:304-315. [PMID: 27784126 DOI: 10.1111/cei.12890] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/07/2016] [Indexed: 12/18/2022] Open
Abstract
Various complement-mediated renal disorders are treated currently with the complement inhibitor eculizumab. By blocking the cleavage of C5, this monoclonal antibody prevents cell damage caused by complement-mediated inflammation. We included 23 patients with atypical haemolytic uraemic syndrome (aHUS, n = 12), C3 glomerulopathies (C3G, n = 9) and acute antibody-mediated renal graft rejection (AMR, n = 2), treated with eculizumab in 12 hospitals in Germany. We explored the course of complement activation biomarkers and the benefit of therapeutic drug monitoring of eculizumab. Complement activation was assessed by analysing the haemolytic complement function of the classical (CH50) and the alternative pathway (APH50), C3 and the activation products C3d, C5a and sC5b-9 prior to, 3 and 6 months after eculizumab treatment. Eculizumab concentrations were determined by a newly established specific enzyme-linked immunosorbent assay (ELISA). Serum eculizumab concentrations up to 1082 μg/ml point to drug accumulation, especially in paediatric patients. Loss of the therapeutic antibody via urine with concentrations up to 56 μg/ml correlated with proteinuria. In aHUS patients, effective complement inhibition was demonstrated by significant reductions of CH50, APH50, C3d and sC5b-9 levels, whereas C5a levels were only reduced significantly after 6 months' treatment. C3G patients presented increased C3d and consistently low C3 levels, reflecting ongoing complement activation and consumption at the C3 level, despite eculizumab treatment. A comprehensive complement analysis together with drug monitoring is required to distinguish mode of complement activation and efficacy of eculizumab treatment in distinct renal disorders. Accumulation of the anti-C5 antibody points to the need for a patient-orientated tailored therapy.
Collapse
Affiliation(s)
- C Wehling
- Institute of Immunology, University of Heidelberg, Heidelberg, Germany
| | - O Amon
- Department of Pediatric Nephrology, University Hospital Tübingen, Germany
| | - M Bommer
- Department of Hematology and Oncology, ALB FILS Hospital Göppingen, Germany
| | - B Hoppe
- Department of Pediatric Nephrology, University Hospital Bonn, Germany
| | - K Kentouche
- Department of Pediatric Immunology, University Hospital Jena, Germany
| | - G Schalk
- Department of Pediatric Nephrology, University Children's Hospital Zurich, Switzerland
| | - R Weimer
- Department of Internal Medicine, University of Giessen, Germany
| | - M Wiesener
- Department of Nephrology and Hypertension, University Hospital Erlangen, Germany
| | - B Hohenstein
- Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany
| | - B Tönshoff
- Department of Pediatrics I, University Children's Hospital Heidelberg, Germany
| | - R Büscher
- Department of Pediatric Nephrology, University Hospital Essen, Germany
| | - H Fehrenbach
- Department of Pediatric Nephrology, Hospital Memmingen, Germany
| | - Ö-N Gök
- Department of Internal Medicine IV, University Hospital Freiburg, Germany
| | - M Kirschfink
- Institute of Immunology, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
13
|
Matthies J, Hünseler C, Ehren R, Volland R, Körber F, Hoppe B, Weber LT, Habbig S. Extrarenal Manifestations in Shigatoxin-associated Haemolytic Uremic Syndrome. Klin Padiatr 2016; 228:181-8. [PMID: 27294341 DOI: 10.1055/s-0042-108444] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Shigatoxin-associated haemolytic uremic syndrome (STEC-HUS) is the most frequent cause of acute kidney injury in children worldwide. Extrarenal manifestations are the main determinants for both, short- and long-term prognosis of patients with STEC-HUS. PATIENTS 46 patients treated over the last 10 years for STEC-HUS in a single center. METHODS This retrospective study analysed the incidence and outcome of extrarenal manifestations in our cohort of children with STEC-HUS. Risk factors for extrarenal involvement and adverse outcome were assessed by detailed chart review. RESULTS Eleven extrarenal manifestations occurred in 9/46 patients comprising 8 neurological, 2 gastro-intestinal, and 1 cardiovascular complication. One patient died from cerebral bleeding. Liver transplantation was required in a girl 18 months after HUS due to secondary sclerosing cholangitis. PATIENTS with extrarenal manifestations were significantly younger and presented with higher leucocyte counts and higher alanine aminotransferase levels at admission. Renal replacement therapy was necessary for a longer period than in patients without extrarenal complications. CONCLUSION Extrarenal manifestations occurred in about 20% of our patients with STEC-HUS. The identification of risk-factors will help to provide a better management of these patients which might also include novel treatment strategies like complement inhibition.
Collapse
Affiliation(s)
- J Matthies
- Division of Pediatric Nephrology, University Children's and Adolescent's Hospital, University Hospital of Cologne, Germany
| | - C Hünseler
- Division of Pediatric Gastroenterology, University Children's and Adolescent's Hospital of Cologne, Germany
| | - R Ehren
- Division of Pediatric Nephrology, University Children's and Adolescent's Hospital, University Hospital of Cologne, Germany
| | - R Volland
- Pediatric Study Center, University Children's Hospital of Cologne, Germany
| | - F Körber
- Division of Pediatric Radiology, Department of Radiology, University Hospital of Cologne, Germany
| | - B Hoppe
- Division of Pediatric Nephrology, University Children's Hospital Bonn, Germany
| | - L T Weber
- Division of Pediatric Nephrology, University Children's and Adolescent's Hospital, University Hospital of Cologne, Germany
| | - S Habbig
- Division of Pediatric Nephrology, University Children's and Adolescent's Hospital, University Hospital of Cologne, Germany
| |
Collapse
|
14
|
Ullmann F, Müller A, Reutter H, Hoppe B. Frühgeborenes mit atypischem hämolytisch-urämischem Syndrom (aHUS). Z Geburtshilfe Neonatol 2015. [DOI: 10.1055/s-0035-1566658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Kurt-Sukur E, Özçakar Z, Fitöz S, Yilmaz S, Hoppe B, Yalçinkaya F. Correction: Primary Hyperoxaluria Type 1: A Cause for Infantile Renal Failure and Massive Nephrocalcinosis. Klin Padiatr 2015; 227:e3. [DOI: 10.1055/s-0035-1555885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- E. Kurt-Sukur
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - Z. Özçakar
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - S. Fitöz
- Department of Radiology, Ankara University School of Medicine, Ankara, Turkey
| | - S. Yilmaz
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - B. Hoppe
- Division of Pediatric Nephrology, Bonn University School of Medicine, Bonn, Germany
| | - F. Yalçinkaya
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| |
Collapse
|
16
|
Kurt-Sukur ED, Özçakar ZB, Fitöz S, Yilmaz S, Hoppe B, Yalçinkaya F. Primary Hyperoxaluria Type 1: A Cause for Infantile Renal Failure and Massive Nephrocalcinosis. Klin Padiatr 2015; 227:293-5. [PMID: 26090995 DOI: 10.1055/s-0035-1554638] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Primary hyperoxaluria type 1 is a rare autosomal-recessive disease caused by the deficient activity of the liver specific enzyme alanine-glyoxylate aminotransferase. Increased endogenous oxalate production induces severe hyperoxaluria, recurrent urolithiasis, progressive nephrocalcinosis and renal failure. Here we report a 6 month old boy who presented with vomiting and decreased urine volume. He was diagnosed with chronic kidney failure at 4 months of age and peritoneal dialysis was introduced at a local hospital. His parents were third degree cousins and family history revealed 2 maternal cousins who developed end stage renal disease during childhood. When he was admitted to our hospital, laboratory studies were consistent with end stage renal disease, ultrasound showed bilateral massive nephrocalcinosis. As clinical presentation was suggestive for primary hyperoxaluria type 1, plasma oxalate was determined and found extremely elevated. Genetic testing proved diagnosis by showing a disease causing homozygous mutation (AGXT-gene: c.971_972delT). The patient was put on pyridoxine treatment and aggressive dialysis programme. In conclusion; progressive renal failure in infancy with massive nephrocalcinosis, especially if accompanied by consanguinity and family history, should always raise the suspicion of PH type 1. Increased awareness of the disease would help physicians in both treating the patients and guiding the families who have diseased children and plan to have further pregnancies.
Collapse
Affiliation(s)
- E D Kurt-Sukur
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - Z B Özçakar
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - S Fitöz
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - S Yilmaz
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| | - B Hoppe
- Division of Pediatric Nephrology, Bonn University School of Medicine, Bonn, Germany
| | - F Yalçinkaya
- Division of Pediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey
| |
Collapse
|
17
|
Flampouri S, Li Z, Hoppe B. SU-E-T-622: Planning Technique for Passively-Scattered Involved-Node Proton Therapy of Mediastinal Lymphoma with Consideration of Cardiac Motion. Med Phys 2015. [DOI: 10.1118/1.4924985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
18
|
Mekahli D, Van Straelen K, Jager K, Schaefer F, Groothoff J, Assadi MH, Landau D, Chen Y, Rabkin R, Medrano J, Segev Y, Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Lastauka I, Coppo R, Laszki-SzczaChor K, Dorota PJ, Zwolinska D, Filipowski H, Rusiecki L, Sobieszczanska M, Dagan R, Davidovits M, Cleper R, Krause I, Chesnaye NC, Jager KJ, Schaefer F, Groothoff JW, Heaf JG, Topaloglu R, Merenmies J, Lewis M, Shtiza D, Maurer E, Zaicova N, Kushnirenko S, Zampetoglou A, Van Stralen KJ, Milo evski-Lomi G, Lezaic V, Radivojevic D, Kostic M, Paripovic D, Peco-Antic A, Benedyk A, Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, Jarosz K, Chrzanowska M, Soltysiak J, Skowronska B, Stankiewicz W, Fichna P, Lewandowska-Stachowiak M, Silska-Dittmar M, Ostalska-Nowicka D, Zachwieja J, Lemoine S, De Souza V, Ranchin B, Cartier R, Pottel H, Dolomanova O, Hadj-Aissa A, Cochat P, Dubourg L, Hoelttae T, Van Stralen KJ, Groothoff JW, Schaefer F, Bjerre A, Jager KJ, Jobs K, Jung A, Lichosik M, Placzynska M, Tjaden LA, Noordzij M, Van Stralen KJ, Schaefer F, Groothoff JW, Jager KJ, Lazzeri E, Ronconi E, Angelotti ML, Peired AJ, Mazzinghi B, Becherucci F, Sansavini G, Sisti A, Provenzano A, Giglio S, Lasagni L, Romagnani P, Pozziani G, Sinatora F, Benetti E, Ghirardo G, Longo G, Cattelan C, Murer L, Malina M, Dusatkova P, Dusek J, Slamova Z, Cinek O, Pruhova S, Bergmann C, Seeman T, Schaefer F, Arbeiter K, Hoppe B, Jungraithmayr T, Klaus G, Pape L, Dinavahi R, Farouk M, Manamley N, Vondrak K, Vidal E, Ranieri M, Ghirardo G, Scavia G, Benetti E, Longo G, Parolin M, Murer L, Aksu N, Yavascan O, Alparslan C, Elmas CH, Saritas S, Anil AB, Kamit Can F, Anil M, Bal A, Kasap Demir B, Mutlubas Ozsan F, Van Huis M, Bonthuis M, Van Stralen KJ, Schaefer F, Jager KJ, Groothoff JW, Makieieva NI, Gramatiuk SM, Tsymbal VM, Buzhynskaya NR, Oborn H, Forinder U, Herthelius M, Westland R, Schreuder MF, Van Der Lof DF, Vermeulen A, Dekker IMJ, Bokenkamp A, Van Wijk JAE, Gramatiuk S, Makieieva NI, Tsymbal VM, Ghirardo G, Seveso M, Della Vella M, Cozzi E, Murer L, Garzotto F, Vidal E, Zanella M, Murer L, Ronco C, Prikhodina L, Chumak O, Dobrynina M, Nusken E, Von Gersdorff G, Schaller M, Rascher K, Barth C, Bach D, Weber L, Dotsch J, Roszkowska-Blaim M, Skrzypczyk P, Jander A, Tkaczyk M, Balasz-Chmielewska I, Zurowska A, Drozdz D, Pietrzyk JA, Aksenova M, Zhetlina V, Mitrofanova A, Choi Y, Cho BS, Suh JS, Abd El-Fattah MA, El-Ghoneimy DH, Elhakim IZ, El-Owaidy RH, Afifi HM, Abo-Elnaga GM, Zvenigorodska A, Tasic V, Gucev Z, Polenakovic M, Silska-Dittmar M, Zaorska K, So tysiak J, Ostalska-Nowicka D, Zachwieja J, Nowicki M, Jobs K, Jung A, Emirova K, Tolstova E, Zaytseva O, Muzurov A, Makulova A, Zverev D, Kamit Can F, Mutlbas Ozsan F, Alparslan C, Elmas CH, Saritas S, Manyas H, Kasap Demir B, Yavascan O, Aksu N, Hoste L, Braat E, De Waele L, Goemans N, Vermeersch P, Gheysens O, Levtchenko E, Pottel H, Golovachova VA, Odinets YV, Zharkova TS, Trynduk YS, Odinets YV, Kharchenko TV, Musial K, Zwolinska D, Roomizadeh P, Gheissari A, Abedini A, Mehdikhani B, Gheissari A, Rezaii Z, Merrikhi A, Madihi Y, Kelishadi R, Dryl IS, Senatorova GS, Kolybaeva TF, Muratov GR, Yavascan O, Aksu N, Alparslan C, Eliacik K, Kanik A, Saritas S, Elmas CH, Mutlubas Ozsan F, Kasap Demir B, Anil M, Bal A, Postorino V, Guzzo G, Ghiotto S, Mazzone L, Loi V, Maxia S, Roggero S, Attini R, Piga A, Postorino M, Pani A, Cabiddu G, Piccoli GB, Peco-Antic A, Kostic M, Spasojevic-Dimitrijeva B, Milosevski-Lomic G, Cvetkovic M, Kruscic D, Paripovic D. PAEDIATRIC NEPHROLOGY. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Hoppe B, Hoppe R. Variable Interpretations of Involved-Site Radiation Therapy Guidelines by Experienced Radiation Oncologists. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Hoppe B, Holtzman A, Li Z, Su Z, Slayton W, Ozdemir S, Joyce M, Sandler E, Mendenhall N, Flampouri S. Advancing the Therapeutic Index of Pediatric Patients with Stage III and IV Hodgkin Lymphoma with Proton Therapy. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Hoppe B. Genetische Diagnostik in der Rheumatologie. AKTUEL RHEUMATOL 2014. [DOI: 10.1055/s-0033-1363690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- B. Hoppe
- Institut für Laboratoriumsmedizin und Pathobiochemie, Charité, Universitätmedizin Berlin Fachbereich Laboratoriumsmedizin & Toxikologie, Labor Berlin – Charité Vivantes GmbH, Berlin
| |
Collapse
|
22
|
Bennett M, Hoppe B, Li Z, Flampouri S. SU-E-J-212: Tracking Dosimetric Changes Due to Lung Patient Physical Changes During Proton Therapy Treatment. Med Phys 2013. [DOI: 10.1118/1.4814424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
23
|
Flampouri S, Hoppe B, Li Z. TH-C-144-07: Proton Lung Planning Based On Beam Specific PTV. Med Phys 2013. [DOI: 10.1118/1.4815801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Pohl M, Dittrich K, Ehrich J, Hoppe B, Kemper M, Klaus G, Schmitt C, Hoyer P. Behandlung der Purpura-Schönlein-Henoch-Nephritis bei Kindern und Jugendlichen. Monatsschr Kinderheilkd 2013. [DOI: 10.1007/s00112-013-2896-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Bryant C, Hoppe B, Nichols R, Henderson R, Mendenhall W, Morris C, Williams C, Su Z, Li Z, Mendenhall N. Does Race Influence Quality of Life, Toxicity, or Early Relapse Following Proton Therapy in Men With Prostate Cancer? Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Marie-Lucile F, Laure-Helene N, Yosr C, Anne M, Fadi F, Levi C, Levi C, Meas-Yedid V, Daniliuc C, Karras A, Olivo-Marin JC, Mouthon L, Guiard E, Roland M, Guillevin L, Jacquot C, Nochy D, Thervet E, Chen Q, Skerka C, Uzonyi B, Lindner S, Licht C, Hoppe B, Riedl M, Kirschfink M, Habbich S, Wolf G, Strain L, Goodship TH, Zipfel PF, Kfoury H, Alsuwaida A, Alsaad K, Alhejaili F, Alghonaim M, Alwakeel J, Husain S, Aloudah N, Besso L, Besso L, Tamagnone M, Daidola G, Burdese M, Repetto L, Pasquale G, Colla L, Biancone L, Stratta P, Segoloni GP, Bacalja J, Bauer Segvic AM, Bulimbasic S, Pacic A, Knotek M, Sabljar Matovinovic M, Galesic K, Galesic Ljubanovic D, Zakharova E, Stolyarevich E, Vorobjova O, Tamouza H, Chemouny JM, Flamant M, Raskova Kafkova L, Demion M, Laurent M, Walker F, Julian BA, Tissandie E, Tiwari MK, Novak J, Camara NO, Benhamou M, Vrtovsnik F, Monteiro RC, Moura IC, Samavat S, Ahmadpoor P, Torbati P, Ghaderi R, Poorrezagholi F, Samadian F, Nafar M, MII A, MII A, Shimizu A, Kaneko T, Yasuda F, Fukui M, Masuda Y, Iino Y, Katayama Y, Muller C, Markovic-Lipkovski J, Simic-Ogrizovic S, Naumovic R, Cirovic S, Mitrovic D, Muller G, Wozniak A, Janicka-Jedynska M, Zurawski J, Kaczmarek E, Zachwieja J, Khilji S, Khilji S, Dorman T, O'kelly P, Lampty L, Leung K, Shadivan A, Varghese C, Walshe J, Saito T, Kawano M, Saeki T, Mizushima I, Yamaguchi Y, Imai N, Nakashima H, Umehara H, Shvetsov M, Popova O, Chebotareva N, Ivanov A, Bobkova I, Cremasco D, Ceol M, Peruzzi L, Mazzucco G, Giuseppina M, Vezzoli G, Cristofaro R, D'angelo A, Anglani F, Del Prete D, Coppolino G, Comi N, Bolignano D, Piraina V, Talarico R, Colombo A, Lucisano G, Fuiano G, Bernich P, Lupo A, Of Renal Biopsies TR, Rastaldi MP, Jercan OC, Messa P, Alexandru D, Mogoanta L, Jercan OC, Shvetsov M, Ivanov A, Uribe Villegas V, Popova O. Renal histopathology. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Nichols R, George T, Zaiden R, Hochwald S, Awad Z, Ho M, Li Z, Mendenhall N, Mendenhall W, Hoppe B. EP-1089 PROTON THERAPY FOR PANCREATIC AND AMPULLARY CANCER IS ASSOCIATED WITH A LOW INCIDENCE OF GASTROINTESTINAL TOXICITY. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71422-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Su Z, Zhao T, Li Z, Hoppe B, Henderson R, Mendenhall W, Nichols C, Marcus R, Mendenhall N. Reduction of Prostate Intrafraction Motion using Gas-release Rectal Balloons. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Huh S, Hoppe B, Zhao T, Li Z. SU-E-J-179: Clinical Application of 40o Very Limited Angle CBCT (VLA CBCT) for Target Localization of Lung Cancer Patient Who Is Treated with SBRT and ABC in Conventional Radiation Therapy. Med Phys 2011. [DOI: 10.1118/1.3611947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Schaar B, Feldkotter M, Nonn JM, Hoppe B. Cardiorespiratory capacity in children and adolescents on maintenance haemodialysis. Nephrol Dial Transplant 2011; 26:3701-8. [DOI: 10.1093/ndt/gfr014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Kummer S, Sagir A, Pandey S, Feldkötter M, Habbig S, Hoppe B, Mayatepek E, Oh J. Leberfibrose bei zystischen Nierenerkrankungen-Anwendung der transienten Elastografie (Fibroscan®) zur Erkennung und Quantifizierung. Klin Padiatr 2011. [DOI: 10.1055/s-0031-1273818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Hoyer-Kuhn HK, Dittrich K, Fehrenbach H, Plum G, Beck B, Hoppe B. Orale Applikation von Oxalobacter formigenes zur Reduktion von Plasmaoxalat-Spiegeln bei der PH I - Zwei Fallberichte. Klin Padiatr 2011. [DOI: 10.1055/s-0031-1273821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Hünseler C, Paneitz A, Friedrich D, Lindner U, Oberthuer A, Körber F, Schmitt K, Welzing L, Müller A, Herkenrath P, Hoppe B, Gortner L, Roth B, Kattner E, Schaible T. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr 2011; 223:10-4. [PMID: 21271514 DOI: 10.1055/s-0030-1269895] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND During a period of 12 months 7 newborns with a partially severe fetopathy caused most probably by maternal sartan-intake in pregnancy were treated in 5 German teaching hospitals. Sartans antagonize the effect of angiotensin II at the AT1-receptor and are used to treat arterial hypertension. METHOD We presented 2 cases at the yearly GNPI meeting 2010 and we were informed about similar cases in other German teaching hospitals which we brought together in this publication. RESULTS In the presented cases, maternal sartan intake was noticed at different times in pregnancy and was in part discontinued some weeks before delivery. In all pregnancies oligohydramnios was present and fetal kidneys displayed a hyperechogenic structure on ultrasound. The newborns' postnatal course varied: oligohydramnios sequence with lung hypoplasia, arterial hypotension and renal insufficiency were the predominant problems of the first days of life. The majority (4/7) of infants did not survive this period, in other cases there was a complete (1/7) recovery of renal function whereas others survived with renal impairment (2/7), in part requiring chronic dialysis. Further distinctive features seen frequently were disturbances of cranial ossification and flaccid paralysis of hands and feet with deviations as well as sensorineural hearing loss. CONCLUSION These case reports again underline the hazardousness of maternal sartan intake with potential fatal outcome for the newborn. Though the use of sartans in pregnancy is contraindicated and several case reports of sartan induced fetopathies exist, the risk of sartan treatment generally seems to be underestimated.
Collapse
Affiliation(s)
- C Hünseler
- Neonatology, Children's Hospital, University of Cologne, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Hünseler C, Oberthür A, Vierzig A, Kribs A, Hoppe B, Roth B. Angiotensin II-Rezeptor Blocker bedingte Fetopathie: 2 Fallberichte. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1261552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Galiano M, Plank C, Dittrich K, Beck B, Hoppe B, Dötsch J. Terminales Nierenversagen in den ersten Lebensmonaten als Erstmanifestation einer Hyperoxalurie Typ I. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1251049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Mendenhall N, Li Z, Morris C, Williams C, Costa J, Hoppe B, Marcus R, Mendenhall W, Nichols R, Henderson R. Early GI and GU Toxicity in Three Prospective Trials of Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.051] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Hoppe B, Häupl T, Egerer K, Gruber R, Kiesewetter H, Salama A, Burmester GR, Dörner T. Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis 2008; 68:898-903. [PMID: 18633125 DOI: 10.1136/ard.2008.091983] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Recent evidence suggests that distinction of subsets of rheumatoid arthritis (RA) depending on anti-cyclic citrullinated peptide antibody (anti-CCP) status may be helpful in distinguishing distinct aetiopathologies and in predicting the course of disease. HLA-DRB1 shared epitope (SE) and peptidylarginine deiminase type 4 (PADI4) genotype, both of which have been implicated in anti-CCP generation, are assumed to be associated with RA. OBJECTIVES To elucidate whether PADI4 affects the clinical characteristics of RA, and whether it would modulate the effect of anti-CCPs on clinical course. The combined effect of SE and PADI4 on autoantibody profile was also analysed. METHODS 373 patients with RA were studied. SE, padi4_94C>T, rheumatoid factor, anti-CCPs and antinuclear antibodies (ANAs) were determined. Disease severity was characterised by cumulative therapy intensity classified into ordinal categories (CTI-1 to CTI-3) and by Steinbrocker score. RESULTS CTI was significantly associated with disease duration, erosive disease, disease activity score (DAS) 28 and anti-CCPs. The association of anti-CCPs with CTI was considerably influenced by padi4_94C>T genotype (C/C: OR(adj) = 0.93, p(adj) = 0.92; C/T: OR(adj) = 2.92, p(adj) = 0.093; T/T: OR(adj) = 15.3, p(adj) = 0.002). Carriage of padi4_94T exhibited a significant trend towards higher Steinbrocker scores in univariate and multivariate analyses. An association of padi4_94C>T with ANAs was observed, with noteworthy differences depending on SE status (SE-: OR(adj) = 6.20, p(adj)<0.04; SE+: OR(adj) = 0.36, p(adj) = 0.02) and significant heterogeneity between the two SE strata (p = 0.006). CONCLUSIONS PADI4 genotype in combination with anti-CCPs and SE modulates clinical and serological characteristics of RA.
Collapse
Affiliation(s)
- B Hoppe
- Central Institute of Laboratory Medicine and Pathobiochemistry, Charité- Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Muller-Berghaus J, Kemper MJ, Hoppe B, Querfeld U, Muller-Wiefel DE, Morahan G, Schadendorf D, Tenbrock K. The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism. Nephrol Dial Transplant 2008; 23:3841-4. [DOI: 10.1093/ndt/gfn395] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Sikora P, von Unruh GE, Beck B, Feldkötter M, Zajaczkowska M, Hesse A, Hoppe B. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008; 73:1181-6. [PMID: 18337715 DOI: 10.1038/ki.2008.63] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Intestinal oxalate absorption is an important part of oxalate metabolism influencing its urinary excretion and its measurement can be a valuable diagnostic tool in hyperoxaluric disorders. In this study, we use [(13)C(2)]oxalate absorption under standardized dietary conditions to assess intestinal oxalate absorption and its impact on urinary oxalate excretion. Tests were conducted in age-matched pediatric patients that included 60 with idiopathic calcium oxalate urolithiasis, 13 with primary hyperoxaluria, and 35 healthy children. In the idiopathic stone formers, median oxalate absorption was significantly higher than that in the controls or in patients with primary disease. From standardized values obtained in control patients, oxalate hyperabsorption was detected in 23 patients with idiopathic disease but not in any patients with primary hyperoxaluria; therefore, a significant correlation between intestinal absorption and urinary excretion was found only in those with the idiopathic disease. We have shown that increased intestinal oxalate absorption is an important risk factor of idiopathic calcium oxalate urolithiasis. In contrast, low intestinal oxalate absorption in patients with primary hyperoxaluria indicates that only foods with excessive oxalate content be restricted from their diet.
Collapse
Affiliation(s)
- P Sikora
- Department of Pediatric Nephrology, Lublin Medical University, Lublin, Poland
| | | | | | | | | | | | | |
Collapse
|
40
|
Körber F, Hoppe B, Lackner KJ. Komplikationen nach sonographisch gesteuerter, perkutaner Nierenbiopsie im Kindesalter – Konsequenzen für das Procedere. ROFO-FORTSCHR RONTG 2008. [DOI: 10.1055/s-2008-1073790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
41
|
Martens I, Hoppe B, Stadler P. Motion pattern of the forelimbs in horses with irregular conformation: a computer based kinematographic analysis. PFERDEHEILKUNDE 2008. [DOI: 10.21836/pem20080601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
42
|
Engel A, Letz M, Zachau T, Pawlowski E, Seneschal-Merz K, Korb T, Enseling D, Hoppe B, Peuchert U, Hayden JS. Reference-based optical characterization of glass-ceramic converter for high-power white LEDs. ACTA ACUST UNITED AC 2007. [DOI: 10.1117/12.705334] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
43
|
Affiliation(s)
- C Goessl
- Department of Gastroenterology, Stiftsklinik Augustinum, Munich, Germany.
| | | | | | | | | |
Collapse
|
44
|
Wolf MTF, Beck BB, Zaucke F, Kunze A, Misselwitz J, Ruley J, Ronda T, Fischer A, Eifinger F, Licht C, Otto E, Hoppe B, Hildebrandt F. The Uromodulin C744G mutation causes MCKD2 and FJHN in children and adults and may be due to a possible founder effect. Kidney Int 2007; 71:574-81. [PMID: 17245395 DOI: 10.1038/sj.ki.5002089] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Autosomal dominant medullary cystic kidney disease type 2 (MCKD2) is a tubulo-in terstitial nephropathy that causes renal salt wasting, hyperuricemia, gout, and end-stage renal failure in the fifth decade of life. This disorder was described to have an age of onset between the age of 20-30 years or even later. Mutations in the Uromodulin (UMOD) gene were published in patients with familial juvenile hyperuricemic nephropathy (FJHN) and MCKD2. Clinical data and blood samples of 16 affected individuals from 11 different kindreds were collected. Mutational analysis of the UMOD gene was performed by exon polymerase chain reaction (PCR) and direct sequencing. We found the heterozygous C744G (Cys248Trp) mutation, which was originally published by our group, in an additional four kindreds from Europe and Turkey. Age of onset ranged from 3 years to 39 years. The phenotype showed a variety of symptoms such as urinary concentration defect, vesicoureteral reflux, urinary tract infections, hyperuricemia, hypertension, proteinuria, and renal hypoplasia. Haplotype analysis showed cosegragation with the phenotype in all eight affected individuals indicating that the C744G mutation may be due to a founder effect. Moreover, we describe a novel T229G (Cys77Gly) mutation in two affecteds of one kindred. Three of the affected individuals were younger than 10 years at the onset of MCKD2/FJHN. Symptoms include recurrent urinary tract infections compatible with the published phenotype of the Umod knockout mouse model. This emphasizes that MCKD2 is not just a disease of the young adult but is also relevant for children.
Collapse
Affiliation(s)
- M T F Wolf
- Department of Pediatric Nephrology of the University Children's Hospital, University of Cologne, Cologne, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
There is ongoing debate about a genotype-phenotype correlation in patients with primary hyperoxaluria type 1 and specific AGXT mutations. However, other determinants like environmental factors or modifer genes may play a pivotal role in the heterogeneity of the disease. The report of Lorenzo and co-workers highlights this situation, presenting data of a whole population with just one specific AGXT mutation.
Collapse
Affiliation(s)
- B B Beck
- Division of Pediatric Nephrology, University Children's Hospital, Cologne, Germany.
| | | |
Collapse
|
46
|
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006; 70:1305-11. [PMID: 16850020 DOI: 10.1038/sj.ki.5001707] [Citation(s) in RCA: 172] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Primary hyperoxaluria is characterized by severe urolithiasis, nephrocalcinosis, and early renal failure. As treatment options are scarce, we aimed for a new therapeutic tool using colonic degradation of endogenous oxalate by Oxalobactor formigenes. Oxalobacter was orally administered for 4 weeks as frozen paste (IxOC-2) or as enteric-coated capsules (IxOC-3). Nine patients (five with normal renal function, one after liver-kidney transplantation, and three with renal failure) completed the IxOC-2 study. Seven patients (six with normal renal function and one after liver-kidney transplantation) completed the IxOC-3 study. Urinary oxalate or plasma oxalate in renal failure was determined at baseline, weekly during treatment and for a 2-week follow-up. The patients who showed >20% reduction both at the end of weeks 3 and 4 were considered as responders. Under IxOC-2, three out of five patients with normal renal function showed a 22-48% reduction of urinary oxalate. In addition, two renal failure patients experienced a significant reduction in plasma oxalate and amelioration of clinical symptoms. Under IxOC-3 treatment, four out of six patients with normal renal function responded with a reduction of urinary oxalate ranging from 38.5 to 92%. Although all subjects under IxOC-2 and 4 patients under IxOC-3 showed detectable levels of O. formigenes in stool during treatment, fecal recovery dropped directly at follow up, indicating only transient gastrointestinal-tract colonization. The preliminary data indicate that O. formigenes is safe, leads to a significant reduction of either urinary or plasma oxalate, and is a potential new treatment option for primary hyperoxaluria.
Collapse
Affiliation(s)
- B Hoppe
- Division of Pediatric Nephrology, University Children's Hospital Cologne, Cologne, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006; 70:42-50. [PMID: 16612335 DOI: 10.1038/sj.ki.5000269] [Citation(s) in RCA: 166] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
We report a novel pathomechanism for membranoproliferative glomerulonephritis type II (MPGN II) caused by a mutant Factor H protein expressed in the plasma. Genetic analyses of two patients revealed deletion of a single Lys residue (K224) located within the complement regulatory region in domain 4 of Factor H. This deletion resulted in defective complement control: mutant protein purified from the plasma of patients showed severely reduced cofactor and decay-accelerating activity, as well as reduced binding to the central complement component C3b. However, cell-binding activity of the mutant protein was normal and comparable to wild-type Factor H. The patients are daughters of consanguineous parents. As both patients but also their healthy mother were positive for C3 nephritic factor, the mutant Factor H protein is considered relevant for unrestricted activation of the disease-causing activation of the alternative complement pathway. Replacement of functional Factor H by fresh frozen plasma (10-15 ml/kg/14 days) was well tolerated, prevented so far disease progression in both patients, and is in the long run expected to preserve kidney function.
Collapse
Affiliation(s)
- C Licht
- Children's Hospital of the University of Cologne, Pediatric Nephrology, Cologne, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Stippel DL, Bangard C, Schleimer K, Koerber F, Beckurts KTE, Hoppe B. Successful Renal Transplantation in a Child With Thrombosis of the Inferior Vena Cava and Both Iliac Veins. Transplant Proc 2006; 38:688-90. [PMID: 16647445 DOI: 10.1016/j.transproceed.2006.01.068] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
An 8-year-old girl who was born premature in the 24th gestational week suffered a septic venous thrombosis due to an indwelling central line during the early perinatal period. As a result the inferior vena cava including the intrahepatic segment and both iliac veins was obliterated. The right kidney was primarily dysplastic, and the left kidney developed a partial infarction. Renal function was compensated until the age of 6 years. Magnetic resonance angiography at that time showed a collateral system via the azygos vein. The venous pressure and its variation with breathing as measured invasively showed normal values. During pretransplant initiation of immunosuppressive therapy, the child developed cerebral convulsions after the third dose of cyclosporine. Therefore we utilized a regimen of rapamycin, mycophenolate mofetil, and steroids. The transplantation was performed using a living donor graft from the child's mother. The relatively long vein from the left kidney was used for anastomosis with a large presacral collateral vein. Twelve months after transplantation the kidney function is stable with a serum creatinine of 0.5 mg/dL. The recipient thrombosis of the caval and iliac veins is not a principal contraindication for successful renal transplantation. MR angiography and invasive pressure measurements facilitated evaluation of the collateral venous system. The living donation setting allowed the initiation of an immunosuppressive regimen that was tailored to the concomitant diseases of the child.
Collapse
Affiliation(s)
- D L Stippel
- Department of Visceral and Vascular Surgery, University of Cologne, Cologne, Germany.
| | | | | | | | | | | |
Collapse
|
49
|
Affiliation(s)
- G A Heymann
- Institute of Transfusion Medicine, Campus Virchow-Klinikum, Charité- Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | | | | | | | | |
Collapse
|
50
|
Martens I, Hoppe B, Carstensen V, Kampmann C, Stadler P. The Examination of the KODAK motion corder analyzer SR 500 as a gait analysis system for horses. PFERDEHEILKUNDE 2006. [DOI: 10.21836/pem20060213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|